Samjo Management LLC Reduces Position in Johnson & Johnson $JNJ

Samjo Management LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,390 shares of the company’s stock after selling 500 shares during the quarter. Johnson & Johnson comprises 1.0% of Samjo Management LLC’s investment portfolio, making the stock its 25th biggest position. Samjo Management LLC’s holdings in Johnson & Johnson were worth $2,351,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Norges Bank purchased a new position in Johnson & Johnson during the second quarter worth approximately $4,877,174,000. Nuveen LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth $1,369,188,000. Laurel Wealth Advisors LLC raised its holdings in shares of Johnson & Johnson by 15,040.6% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock worth $1,133,512,000 after acquiring an additional 7,371,687 shares during the period. Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after acquiring an additional 3,085,180 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Johnson & Johnson by 159.6% in the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after purchasing an additional 2,557,388 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on JNJ. Morgan Stanley set a $190.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Raymond James Financial lifted their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. UBS Group increased their price objective on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. Argus set a $210.00 target price on Johnson & Johnson in a research report on Wednesday, October 15th. Finally, Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $201.05.

Johnson & Johnson Stock Down 0.3%

Johnson & Johnson stock opened at $206.89 on Monday. The company has a market capitalization of $498.46 billion, a PE ratio of 19.97, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $207.81. The firm has a 50 day moving average price of $191.33 and a 200 day moving average price of $173.72.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion during the quarter. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.